However, a discordant HER2 status was found between CTC-positive cases and corresponding primary tumors (HER2-positive CTCs/ HER2-negative primary tumor tissue), suggesting that primary HER2-negative tumors acquired HER2 gene amplification in their CTCs during cancer progression. The gene discussed is ERBB2; the disease is neoplasm.